There is evidence in the literature that shows inhibition of ABCB5 either at the protein or mRNA level can inhibit doxorubicin transport and also sensitize melanoma and liver cancer stem cells to the drug [9], [14]. The gene discussed is ABCB5; the disease is melanoma.